Drugs / CE-Iohexol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04627831 | Jan 2022 → Mar 2023 | — | Ligand Pharmaceuticals | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-11-08 | Ligand Pharmaceuticals | Results Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol ligand.com ↗
The trial achieved the primary endpoint demonstrating pharmacokinetic bioequivalence between CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE™) after intravenous (IV) administration in healthy adults. |
| 2019-07-10 | Ligand Pharmaceuticals | Results Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol ligand.com ↗
Based on top line data, the trial achieved the primary endpoint demonstrating pharmacokinetic bioequivalence between CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE™) after intravenous (IV) administration in healthy adults. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-11-08 | Ligand Pharmaceuticals | Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol ligand.com ↗ |
| 2019-07-10 | Ligand Pharmaceuticals | Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol ligand.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CE-Iohexol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627831 ↗ |
| Modality | Diagnostic / imaging agent | “Captisol-Enabled™ Iohexol as needed for the diagnostic procedure” NCT04627831 ↗ |